Inclusion Criteria:  Patient with pathologically confirmed HCC not amenable to curative resection, transplantation or ablative therapies Have radiographically measurable disease by RECIST Eligible for atezolizumab/bevacizumab front line therapy Male or female with age greater than 18 years, with the capacity and willingness to provide written informed consent  Exclusion Criteria:  Pregnant and/or breast-feeding patients. A negative pregnancy test within 48 hours of the PET scan Patients with higher than the weight/size limitations of PET/CT scanner